Literature DB >> 8787917

Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa.

K C Lamp1, M J Rybak, B J McGrath, K K Summers.   

Abstract

Recent controversy surrounding the activity of monoclonal antibodies against endotoxin highlights the necessity of identifying all factors associated with increased mortality, one of which is endotoxin concentrations. Antibiotics may induce different patterns of endotoxin release. We compared the release of free endotoxin (in endotoxin units per milliliter) over 6 h and changes in numbers of CFU of exponentially growing Escherichia coli and Pseudomonas aeruginosa (10(6) to 10(7) CFU/ml) cultured in chemically defined endotoxin-free broth combined with pooled human serum and/or 10 micrograms of E5 immunoglobulin M monoclonal antibody per ml. MICs and MBCs were tested in each medium at the same inoculum. The inoculum was exposed to antibiotics at a single fixed multiple of the MIC for each medium (range, two to eight times the MIC). E5 antibody had no effect on MICs, MBCs, bactericidal activity, or endotoxin release. In the presence of 50% serum, amikacin, ceftazidime, imipenem, and ofloxacin each killed equivalent amounts of E. coli over 6 h; however, ceftazidime induced the highest release of endotoxin. Amikacin and ofloxacin produced the most favorable ratio of endotoxin release to amount of bacterial killing. In the presence of 50% serum, ceftazidime and imipenem reduced the P. aeruginosa inoculum to the greatest extent over 6 h. Although its bactericidal activity was diminished, ofloxacin caused the lowest release of free endotoxin. Imipenem and ofloxacin showed similar low ratios of endotoxin release to bacterial killing. In summary, antibiotic class, presence of serum, and type of organism influenced bactericidal activity and endotoxin release.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787917      PMCID: PMC163094     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Anti-endotoxin monoclonal antibodies.

Authors:  H S Warren; R L Danner; R S Munford
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

2.  Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study.

Authors:  A S Dofferhoff; J H Nijland; H G de Vries-Hospers; P O Mulder; J Weits; V J Bom
Journal:  Scand J Infect Dis       Date:  1991

3.  beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime.

Authors:  J J Jackson; H Kropp
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

Review 4.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

5.  Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.

Authors:  A Waage; A Halstensen; T Espevik
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

6.  Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit.

Authors:  B Guidet; V Barakett; T Vassal; J C Petit; G Offenstadt
Journal:  Chest       Date:  1994-10       Impact factor: 9.410

7.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

Review 8.  The pathogenesis of sepsis.

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1991-09-15       Impact factor: 25.391

9.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

Authors:  R L Greenman; R M Schein; M A Martin; R P Wenzel; N R MacIntyre; G Emmanuel; H Chmel; R B Kohler; M McCarthy; J Plouffe
Journal:  JAMA       Date:  1991-08-28       Impact factor: 56.272

10.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease.

Authors:  P Brandtzaeg; P Kierulf; P Gaustad; A Skulberg; J N Bruun; S Halvorsen; E Sørensen
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

View more
  5 in total

Review 1.  The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

Authors:  R G Holzheimer
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

2.  Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli.

Authors:  T Kirikae; F Kirikae; S Saito; K Tominaga; H Tamura; Y Uemura; T Yokochi; M Nakano
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections.

Authors:  Nazir A Barekzi; Adrian G Felts; Kornelis A Poelstra; Jeffrey B Slunt; David W Grainger
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

4.  Zingerone suppresses liver inflammation induced by antibiotic mediated endotoxemia through down regulating hepatic mRNA expression of inflammatory markers in Pseudomonas aeruginosa peritonitis mouse model.

Authors:  Lokender Kumar; Sanjay Chhibber; Kusum Harjai
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

5.  Porcine reproductive-respiratory syndrome virus infection predisposes pigs for respiratory signs upon exposure to bacterial lipopolysaccharide.

Authors:  G Labarque; K Van Reeth; S Van Gucht; H Nauwynck; M Pensaert
Journal:  Vet Microbiol       Date:  2002-08-02       Impact factor: 3.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.